DE69735804D1 - Hautpenetrationsförderer sowie diese verwendende arzneiverabreichungssysteme - Google Patents

Hautpenetrationsförderer sowie diese verwendende arzneiverabreichungssysteme

Info

Publication number
DE69735804D1
DE69735804D1 DE69735804T DE69735804T DE69735804D1 DE 69735804 D1 DE69735804 D1 DE 69735804D1 DE 69735804 T DE69735804 T DE 69735804T DE 69735804 T DE69735804 T DE 69735804T DE 69735804 D1 DE69735804 D1 DE 69735804D1
Authority
DE
Germany
Prior art keywords
penetration enhancer
dermal
active agent
physiologically active
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69735804T
Other languages
English (en)
Other versions
DE69735804T2 (de
Inventor
Leonard Reed
Matthias Morgan
Charles Finnin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acrux DDS Pty Ltd
Original Assignee
Acrux DDS Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3792458&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69735804(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acrux DDS Pty Ltd filed Critical Acrux DDS Pty Ltd
Application granted granted Critical
Publication of DE69735804D1 publication Critical patent/DE69735804D1/de
Publication of DE69735804T2 publication Critical patent/DE69735804T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/046—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A61K8/445—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof aromatic, i.e. the carboxylic acid directly linked to the aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M35/00—Devices for applying media, e.g. remedies, on the human body
    • A61M35/003—Portable hand-held applicators having means for dispensing or spreading integral media
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE69735804T 1996-02-19 1997-02-19 Hautpenetrationsförderer sowie diese verwendende arzneiverabreichungssysteme Expired - Lifetime DE69735804T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPN8144A AUPN814496A0 (en) 1996-02-19 1996-02-19 Dermal penetration enhancer
AUPN814496 1996-02-19
PCT/AU1997/000091 WO1997029735A1 (en) 1996-02-19 1997-02-19 Dermal penetration enhancers and drug delivery systems involving same

Publications (2)

Publication Number Publication Date
DE69735804D1 true DE69735804D1 (de) 2006-06-08
DE69735804T2 DE69735804T2 (de) 2006-12-14

Family

ID=3792458

Family Applications (6)

Application Number Title Priority Date Filing Date
DE69739037T Expired - Lifetime DE69739037D1 (de) 1996-02-19 1997-02-19 Hautpenetrationsförderer sowie diese verwendende Arzneiverabreichungssysteme
DE69735804T Expired - Lifetime DE69735804T2 (de) 1996-02-19 1997-02-19 Hautpenetrationsförderer sowie diese verwendende arzneiverabreichungssysteme
DE69739931T Expired - Lifetime DE69739931D1 (de) 1996-02-19 1997-02-19 Hautpenetrationsförderer sowie diese verwendende Arzneiverabreichungssysteme
DE201212000020 Pending DE122012000020I1 (de) 1996-02-19 2012-04-03 Hautpenetrationsforderer sowie diese verwendende arzneiverabreichungssysteme.
DE201212000019 Pending DE122012000019I1 (de) 1996-02-19 2012-04-03 Hautpenetrationsforderer sowie diese verwendende Arzneiverabreichungssysteme.
DE201212000021 Pending DE122012000021I1 (de) 1996-02-19 2012-04-03 Hautpenetrationsforderer sowie diese verwendende.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69739037T Expired - Lifetime DE69739037D1 (de) 1996-02-19 1997-02-19 Hautpenetrationsförderer sowie diese verwendende Arzneiverabreichungssysteme

Family Applications After (4)

Application Number Title Priority Date Filing Date
DE69739931T Expired - Lifetime DE69739931D1 (de) 1996-02-19 1997-02-19 Hautpenetrationsförderer sowie diese verwendende Arzneiverabreichungssysteme
DE201212000020 Pending DE122012000020I1 (de) 1996-02-19 2012-04-03 Hautpenetrationsforderer sowie diese verwendende arzneiverabreichungssysteme.
DE201212000019 Pending DE122012000019I1 (de) 1996-02-19 2012-04-03 Hautpenetrationsforderer sowie diese verwendende Arzneiverabreichungssysteme.
DE201212000021 Pending DE122012000021I1 (de) 1996-02-19 2012-04-03 Hautpenetrationsforderer sowie diese verwendende.

Country Status (15)

Country Link
US (8) US6299900B1 (de)
EP (3) EP0901368B1 (de)
JP (2) JP4213211B2 (de)
KR (1) KR100528602B1 (de)
AT (3) ATE410136T1 (de)
AU (2) AUPN814496A0 (de)
CA (1) CA2244089C (de)
DE (6) DE69739037D1 (de)
DK (3) DK1674068T3 (de)
ES (3) ES2262173T3 (de)
HK (3) HK1018884A1 (de)
LU (3) LU91971I2 (de)
NZ (1) NZ330942A (de)
PT (3) PT1769785E (de)
WO (1) WO1997029735A1 (de)

Families Citing this family (367)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861571B1 (en) * 1994-11-28 2005-03-01 The Procter & Gamble Company Article having a lotioned topsheet
BR9509985A (pt) 1995-12-12 1998-11-03 Omeros Med Sys Inc Solução para irrigação e método para inibição de dor inflamação e esparmo
US6413961B1 (en) 1995-12-12 2002-07-02 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
US6923983B2 (en) * 1996-02-19 2005-08-02 Acrux Dds Pty Ltd Transdermal delivery of hormones
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US6916487B2 (en) * 1996-02-19 2005-07-12 Acrux Dds Pty Ltd Transdermal delivery of antiemetics
US6916486B2 (en) * 1996-02-19 2005-07-12 Acrux Dds Pty Ltd Transdermal delivery of analgesics
US7094422B2 (en) * 1996-02-19 2006-08-22 Acrux Dds Pty Ltd. Topical delivery of antifungal agents
US6929801B2 (en) * 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US6512010B1 (en) * 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US8022095B2 (en) * 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
GR1002847B (el) 1997-05-06 1998-01-27 Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως
US6767902B2 (en) * 1997-09-17 2004-07-27 The Population Council, Inc. Androgen as a male contraceptive and non-contraceptive androgen replacement
US20030095925A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
US20090162300A1 (en) * 1997-10-01 2009-06-25 Dugger Iii Harry A Buccal, polar and non-polar spray containing alprazolam
EP1036561A1 (de) * 1997-10-01 2000-09-20 Flemington Pharmaceutical Corporation Nichtpolare Spray zur bukkalen Anwendung
US20050002867A1 (en) * 1997-10-01 2005-01-06 Novadel Pharma Inc. Buccal, polar and non-polar sprays containing propofol
US20030190286A1 (en) * 1997-10-01 2003-10-09 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma
US20030095927A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
US20050281752A1 (en) * 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US7632517B2 (en) * 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US20040141923A1 (en) * 1997-10-01 2004-07-22 Dugger Harry A. Buccal, polar and non-polar spray containing alprazolam
US20040136913A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing sumatriptan
US20050163719A1 (en) * 1997-10-01 2005-07-28 Dugger Harry A.Iii Buccal, polar and non-polar spray containing diazepam
US20040136914A1 (en) 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US20030185761A1 (en) * 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US20030082107A1 (en) * 1997-10-01 2003-05-01 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
US20030077228A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders
US20050180923A1 (en) * 1997-10-01 2005-08-18 Dugger Harry A.Iii Buccal, polar and non-polar spray containing testosterone
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US20040136915A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing atropine
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20050287075A1 (en) * 1997-10-01 2005-12-29 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US5968919A (en) * 1997-10-16 1999-10-19 Macrochem Corporation Hormone replacement therapy drug formulations for topical application to the skin
US7098206B2 (en) 1998-01-21 2006-08-29 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6998400B2 (en) 1998-01-22 2006-02-14 Smithkline Beecham Corporation Pharmaceutically active morpholinol
JP2002501891A (ja) * 1998-01-29 2002-01-22 セプラコア インコーポレーテッド 光学的に純粋な（＋）−ビュープロピオンの医薬用途
CA2318738A1 (en) * 1998-01-29 1999-08-05 Sepracor Inc. Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (-)-bupropion
JP2002501892A (ja) 1998-01-29 2002-01-22 セプラコア インコーポレーテッド 光学的に純粋な（−）−ビュープロピオンの薬学的使用
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
IL124764A0 (en) * 1998-06-04 1999-01-26 Univ Ben Gurion Topical composition for treatment of baldness
DE19825591A1 (de) * 1998-06-09 1999-12-23 Jenapharm Gmbh Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata
GR1003199B (el) 1998-08-14 1999-09-01 Χρηση της μισοπροστολης ή και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση της σεξουαλικης δυσλειτουργιας στις γυναικες
CA2341220A1 (en) 1998-08-20 2000-03-02 3M Innovative Properties Company Spray on bandage and drug delivery system
BR9916963A (pt) * 1998-12-08 2002-03-05 Planisphere Corp Bupropiona para tratamento de doenças virais
GB9828480D0 (en) * 1998-12-24 1999-02-17 Dermatech Limited Transdermal drug delivery system
DE60036915T2 (de) 1999-01-13 2008-08-07 Alchemia Oncology Pty Ltd., Hawthorn Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln
US6855820B2 (en) 1999-01-20 2005-02-15 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6734213B2 (en) 1999-01-20 2004-05-11 Smithkline Beecham Corporation Pharmaceutically active morpholinol
KR100390870B1 (ko) * 1999-02-09 2003-07-10 주식회사 삼양사 경피투여용 항구토제 조성물 및 이를 포함하는 제제
US6342496B1 (en) 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
KR20010108316A (ko) 1999-03-05 2001-12-07 데이비드 엠 모이어 Ｃ16 불포화된 ｆｐ-선택적 프로스타글란딘 유사체
DE19918105C1 (de) * 1999-04-22 2000-09-21 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit einem stark wirksamen Neuroleptikum
US6428769B1 (en) * 1999-05-04 2002-08-06 Aradigm Corporation Acute testosterone administration
US6632419B2 (en) 1999-05-04 2003-10-14 Aradigm Corporation Increasing libido in humans via acute testosterone administration
EP1175204A4 (de) * 1999-05-04 2006-05-31 Aradigm Corp Aerosolformulierung und artikel zur steigerung der libido bei frauen durch momentane testosteronverabreichung
US7258850B2 (en) 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
US6312716B1 (en) * 1999-05-10 2001-11-06 Peierce Management Llc Patch and method for transdermal delivery of bupropion base
US6280763B1 (en) 1999-05-10 2001-08-28 Pierce Management, Llc Apparatus and method for transdermal delivery of bupropion
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US6595947B1 (en) * 2000-05-22 2003-07-22 Becton, Dickinson And Company Topical delivery of vaccines
US7241731B2 (en) 2000-06-05 2007-07-10 Sumitomo Electric Industries, Ltd. Oligopeptides for promoting hair growth
US20050008602A1 (en) * 2000-06-05 2005-01-13 Sumitomo Electric Industries, Ltd. Oligopeptides for promoting hair growth
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
ATE485837T1 (de) 2000-08-03 2010-11-15 Antares Pharma Ipl Ag Zusammensetzung zur transdermalen und/oder transmukosalen verabreichung von wirkstoffen, die ausreichende therapeutische spiegel garantiert
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10041479A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
DE10053397A1 (de) 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10042411A1 (de) * 2000-08-30 2002-03-28 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Abgabe von Exemestan
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
EP1315502B1 (de) * 2000-08-30 2010-03-17 Unimed Pharmaceuticals, LLC Verfahren zur behandlung von erektionsstörungen und steigerung der libido bei männern
AU2001289865B2 (en) * 2000-09-08 2007-03-01 Pharmacia Italia S.P.A. Exemestane as chemopreventing agent
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
US20020177626A1 (en) 2001-01-19 2002-11-28 Cook Graham D. Treatment of sleep disturbances
FR2815256A1 (fr) * 2001-01-23 2002-04-19 Oreal Composition, notamment cosmetique, comprenant au moins un derive de sapogenine et au moins un solubilisant du derive de sapogenine
JP3767392B2 (ja) * 2001-02-05 2006-04-19 日産自動車株式会社 エンジンのカム軸回転位相検出装置及びシリンダ吸入空気量算出装置
US20020172732A1 (en) * 2001-03-21 2002-11-21 Wies Ter Laak Composition comprising cocoa
US20030027793A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
US20030026830A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
US7498019B2 (en) 2001-05-24 2009-03-03 Alexza Pharmaceuticals, Inc. Delivery of compounds for the treatment of headache through an inhalation route
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
EP1392262A1 (de) 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Verabreichung von arzneimittel-estern durch inhalation
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
EP1408896B1 (de) * 2001-06-22 2016-01-20 CPEX Pharmaceuticals, Inc. Pharmazeutische zusammensetzung
US7244703B2 (en) 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
US20040138239A1 (en) * 2001-08-23 2004-07-15 Bruce Frome Compositions and methods for targeting cerebral circulation and treatment of headache
WO2003018023A1 (en) * 2001-08-23 2003-03-06 Bruce Frome Compositions and methods for targeting cerebral circulation and treatment of headache
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
EP1427447A4 (de) * 2001-08-27 2007-05-23 Alchemia Oncology Ltd Verbesserte therapieprotokolle
US6723077B2 (en) * 2001-09-28 2004-04-20 Hewlett-Packard Development Company, L.P. Cutaneous administration system
US20040120964A1 (en) * 2001-10-29 2004-06-24 Mikszta John A. Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses
ATE420676T1 (de) * 2001-10-29 2009-01-15 Becton Dickinson Co Vorrichtung für die abgabe einer substanz
US7037513B1 (en) 2005-01-31 2006-05-02 Aquea Scientific Corporation Bodywash additives
US6998113B1 (en) 2005-01-31 2006-02-14 Aquea Scientific Corporation Bodywashes containing additives
US7025952B1 (en) 2005-01-31 2006-04-11 Aquea Scientific Corporation Methods of preparation and use of bodywashes containing additives
US20060173709A1 (en) * 2005-01-31 2006-08-03 Traynor Daniel H Bodywash additive business methods
MXPA04006017A (es) 2001-12-20 2005-06-08 Femmepharma Inc Suministro de farmacos por via vaginal.
US20040097871A1 (en) * 2002-01-03 2004-05-20 Israel Yerushalmy Apparatus for treating sleep disorders
US20030143165A1 (en) * 2002-01-25 2003-07-31 Allan Evans NSAID-containing topical formulations that demonstrate chemopreventive activity
US20030161802A1 (en) * 2002-02-05 2003-08-28 Flammer Linda J. Anti-dandruff and anti-itch compositions containing sensate and sensate enhancer-containing compounds
AU2003238543B2 (en) * 2002-06-25 2008-02-28 Acrux Dds Pty Ltd Transdermal aerosol compositions
US20050181032A1 (en) * 2002-06-25 2005-08-18 Acrux Dds Pty Ltd. Metastable pharmaceutical compositions
NZ537359A (en) * 2002-06-25 2006-10-27 Cosmeceutic Solutions Pty Ltd Topical cosmetic compositions for transdermal delivery
AUPS317302A0 (en) * 2002-06-25 2002-07-18 Drug Delivery Solutions Pty Ltd Metastable pharmaceutical compositions
AUPS317102A0 (en) * 2002-06-25 2002-07-18 Drug Delivery Solutions Pty Ltd Transdermal aerosol compositions
US20050186141A1 (en) * 2002-06-25 2005-08-25 Acrux Dds Pty Ltd. Transdermal aerosol compositions
NZ537360A (en) 2002-06-25 2006-09-29 Acrux Dds Pty Ltd Transdermal delivery rate control using amorphous pharmaceutical compositions
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
EP1386605A1 (de) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Verbessertes transdermales System für die Verabreichung von Rotigotin
DE10234673B4 (de) 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
KR101108439B1 (ko) 2002-10-25 2012-01-31 포믹스 리미티드 화장료 및 약제용 거품제
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US20040086579A1 (en) * 2002-11-05 2004-05-06 Higgins James W. Dietary supplement comprising parthenolide
US7192614B2 (en) 2002-11-05 2007-03-20 Gelstat Corporation Compositions and methods of treatment to alleviate or prevent migrainous headaches and their associated symptoms
US7374772B2 (en) * 2002-11-07 2008-05-20 Bommarito Alexander A Topical antifungal treatment
AU2003295823B2 (en) * 2002-11-26 2009-11-05 Alexza Pharmaceuticals, Inc. Treatment of headache with antipsychotics delivered by inhalation
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
JP2006514934A (ja) 2002-11-26 2006-05-18 アレックザ ファーマシューティカルズ， インコーポレイテッド 疼痛治療用薬剤製造のためのロキサピンまたはアモキサピンの使用
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
EP1426049B1 (de) * 2002-12-02 2005-05-18 Schwarz Pharma Ag Verabreichung von Rotigotine zur Behandlung der Parkinson'schen Krankheit durch Iontophorese
US20040220198A1 (en) * 2002-12-20 2004-11-04 Kasturi Haldar Methods for treating malaria by modulation of G protein function
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
EP1578421A4 (de) * 2003-01-02 2009-04-22 Femmepharma Holding Co Inc Pharmazeutische präparate für diebehandlung von erkrankungen und pathologischen zuständen der brust
US20040247707A1 (en) * 2003-01-06 2004-12-09 Le Roy Charles Richard Pearl blue fast acting, long lasting topical pain relief cream
EA010871B1 (ru) 2003-01-23 2008-12-30 Шир Холдингз Аг Трансдермальные составы и способы лечения тромбоцитемии
EP1444976A1 (de) * 2003-02-10 2004-08-11 Novadel Pharma Inc. Bukkale, polare und nichtpolare Spray und Kapsel
ITFI20030070A1 (it) * 2003-03-18 2004-09-19 Berlin Chemie Ag Formulazioni topiche stabilizzate contenenti ketoprofene
EP1610742B1 (de) 2003-04-10 2015-01-21 Neurogesx, Inc. Verwendung und zusammensetzungen zur verabreichung von capsaicin
US7361376B2 (en) * 2003-04-11 2008-04-22 International Flavors & Fragrances Inc. Alkyldienamides exhibiting taste and sensory effect in flavor compositions
US7632531B2 (en) * 2003-04-11 2009-12-15 International Flavors & Fragnances Inc. Alkyldienamides exhibiting taste and sensory effect in flavor compositions
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
JP2007516404A (ja) 2003-05-21 2007-06-21 アレックザ ファーマシューティカルズ， インコーポレイテッド 光学点火されたかまたは電気点火された内蔵式加熱ユニットおよびそれを使用する薬剤供給ユニット
US20040247705A1 (en) * 2003-06-06 2004-12-09 Roberts Stephen C. Transdermal compositions and methods of treatment to alleviate or prevent migrainous headaches and their associated symptoms
US20040247706A1 (en) * 2003-06-06 2004-12-09 Roberts Stephen C. Transdermal dietary supplement comprising parthenolide
US20040259852A1 (en) * 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
US8883769B2 (en) * 2003-06-18 2014-11-11 White Mountain Pharma, Inc. Methods for the treatment of fibromyalgia and chronic fatigue syndrome
EP1488787A1 (de) * 2003-06-20 2004-12-22 Berlin-Chemie Ag Topisch anzuwendende stabilisierte Arzneimittel enthaltend Ketoprofen
CA2433101A1 (en) * 2003-06-23 2004-12-23 Igor Gonda Method of treatment of a female suffering from androgen insufficiency
US20050042182A1 (en) * 2003-08-13 2005-02-24 Moshe Arkin Topical compositions of urea
US20050036953A1 (en) * 2003-08-13 2005-02-17 Moshe Arkin Topical compositions of ammonium lactate
US20050037040A1 (en) * 2003-08-13 2005-02-17 Moshe Arkin Topical compositions of urea and ammonium lactate
US6884906B2 (en) * 2003-07-01 2005-04-26 International Flavors & Fragrances Inc. Menthyl half acid ester derivatives, processes for preparing same, and uses thereof for their cooling/refreshing effect in consumable materials
US7141686B2 (en) * 2003-07-10 2006-11-28 International Flavors & Fragrances Inc. E2, E4, Z8-undecatrienoic acid and ester and carboxamide derivatives thereof, organoleptic uses thereof and processes for preparing same
US20050042268A1 (en) * 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050020552A1 (en) * 2003-07-16 2005-01-27 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050025833A1 (en) * 2003-07-16 2005-02-03 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
DE10334188B4 (de) 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
EP1651197A1 (de) 2003-07-28 2006-05-03 ALZA Corporation Transdermales warfarin enthaltendes abgabesystem
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
WO2005016321A1 (en) * 2003-08-15 2005-02-24 Qlt Usa, Inc. Adhesive bioerodible transmucosal drug delivery system
US20060018852A1 (en) * 2003-08-22 2006-01-26 L'oreal Compositions containing topical active agents and pentylene glycol
US20050043283A1 (en) * 2003-08-22 2005-02-24 L'oreal S.A. Compositions containing topical active agents and pentylene glycol
US20060263350A1 (en) * 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
US7329767B2 (en) * 2003-10-03 2008-02-12 International Flavors & Fragrances Inc. Conjugated dienamides, methods of production thereof, compositions containing same and uses thereof
US8007839B2 (en) * 2003-10-03 2011-08-30 International Flavors & Fragrances Conjugated dienamides, methods of production thereof, compositions containing same and uses thereof
US7387788B1 (en) 2003-10-10 2008-06-17 Antares Pharma Ipl Ag Pharmaceutical compositions of nicotine and methods of use thereof
MXPA06003316A (es) 2003-10-10 2006-06-08 Antares Pharma Ipl Ag Formulacion farmaceutica transdermica para minimizar los residuos en la piel.
KR100552650B1 (ko) * 2003-11-17 2006-02-20 아이큐어 주식회사 피록시캄 함유 소염진통용 플라스터
US20050129756A1 (en) * 2003-12-10 2005-06-16 Hans-Peter Podhaisky UV-stable, liquid or semisolid transdermal pharmaceutical preparation with light sensitive active ingredient
EP1541136A1 (de) * 2003-12-10 2005-06-15 Schering AG UV-Licht stabile halbfeste transdermale Systeme, die einen lichtempfindlichen Wirkstoff und einen UV-Absorber enthalten
JP2007520262A (ja) * 2003-12-10 2007-07-26 アクルックス・ディ・ディ・エス・プロプライエタリー・リミテッド 経皮または局所薬物輸送に伴う副作用の処置方法
EP1547592A1 (de) 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasale formulierung enthaltend
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
US7425340B2 (en) * 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
US8741333B2 (en) 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for treating dermatitis or psoriasis
US8741332B2 (en) 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for dermally treating neuropathic pain
US8907153B2 (en) * 2004-06-07 2014-12-09 Nuvo Research Inc. Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same
EP1765300A2 (de) * 2004-06-10 2007-03-28 Duramed Pharmaceuticals, Inc. Formulierungen von sumatriptan zur absorption durch biologische membranen, und herstellungs- und anwendungsverfahren
US7700608B2 (en) * 2004-08-04 2010-04-20 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia
US20060030574A1 (en) * 2004-08-04 2006-02-09 Shire Holdings Ag Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors
US20070264319A1 (en) * 2004-09-01 2007-11-15 Lebo David B Transdermal Antiemesis Delivery System, Method and Composition Therefor
US7427421B2 (en) * 2004-09-10 2008-09-23 International Flavors & Fragrances Inc. Saturated and unsaturated N-alkamides exhibiting taste and flavor enhancement effect in flavor compositions
US7541055B2 (en) * 2004-09-10 2009-06-02 International Flavors & Fragrances Inc. Saturated and unsaturated N-alkamides exhibiting taste and flavor enhancement effect in flavor compositions
US8252320B2 (en) 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
NZ582975A (en) 2004-10-21 2011-07-29 Durect Corp Transdermal delivery systems delivering sufentanil
US7001592B1 (en) 2005-01-31 2006-02-21 Aquea Scientific Corporation Sunscreen compositions and methods of use
WO2006084312A1 (en) * 2005-02-09 2006-08-17 Acrux Dds Pty Ltd Method of promoting hair growth
CA2597651A1 (en) * 2005-02-14 2006-08-24 Neurogesx, Inc. Device for delivery of trpv1 agonists
ES2490595T3 (es) 2005-02-17 2014-09-04 Abbott Laboratories Administración transmucosal de composiciones de fármacos para tratar y prevenir trastornos en animales
US20080112904A1 (en) * 2005-03-08 2008-05-15 Daniel Henry Traynor Sunscreen Compositions And Methods Of Use
WO2006102267A2 (en) 2005-03-21 2006-09-28 The Trustees Of Columbia University In The City Of New York New neuronal pain pathway
AU2006227561B2 (en) * 2005-03-24 2011-06-09 Ensign Laboratories Pty Ltd Sunscreen aerosol spray
WO2006099687A1 (en) * 2005-03-24 2006-09-28 Ensign Laboratories Pty Ltd Sunscreen aerosol spray
WO2006105481A1 (en) * 2005-03-30 2006-10-05 Neurogesx, Inc. Low-concentration capsaicin patch and methods for treating neuropathic pain
US20060222692A1 (en) * 2005-03-31 2006-10-05 Fairfield Clinical Trials Llc Method and compositions for transdermal administration of antimicrobial medications
WO2007124250A2 (en) 2006-04-21 2007-11-01 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
BRPI0612931B8 (pt) * 2005-05-16 2021-05-25 Novapharm Res Australia Pty Ltd composição para aplicação na pele
US8067399B2 (en) 2005-05-27 2011-11-29 Antares Pharma Ipl Ag Method and apparatus for transdermal or transmucosal application of testosterone
ES2607454T3 (es) 2005-06-03 2017-03-31 Acrux Dds Pty Ltd Método y composición para el suministro transdérmico de testosterona
WO2006128255A1 (en) 2005-06-03 2006-12-07 Acrux Dds Pty Ltd Method and composition for transdermal drug delivery
JP4696701B2 (ja) 2005-06-07 2011-06-08 ソニー株式会社 抵抗回路
RU2408368C2 (ru) * 2005-06-27 2011-01-10 Биовэйл Лэборэториз Интернэшнл С.Р.Л. Препараты соли бупропиона с модифицированным высвобождением
KR100699582B1 (ko) 2005-07-11 2007-03-23 삼성전기주식회사 출력 버퍼회로
WO2007012133A1 (en) * 2005-07-27 2007-02-01 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
DK1909778T3 (en) * 2005-07-28 2018-03-19 Academisch Ziekenhuis Bij De Univ Van Amsterdam Monophenol, benzenediol or sulfhydryl compounds for use in the treatment of melanomas
EA013877B1 (ru) * 2005-09-07 2010-08-30 Алкемиа Онколоджи Пти Лимитед Терапевтические композиции, содержащие гиалуроновую кислоту и терапевтические антитела, а также способы лечения
PT1937276E (pt) 2005-10-12 2013-02-21 Besins Healthcare Luxembourg Gel de testosterona melhorado e método para a sua utilização
US20070087055A1 (en) * 2005-10-14 2007-04-19 David Jan Directly compressible extended release alprazolam formulation
DE112006002834T5 (de) 2005-11-04 2008-10-30 Acrux DDS Pty. Ltd., West Melbourne Verfahren und System für eine transdermale Arzneimittelzufuhr
CA2629560A1 (en) * 2005-11-21 2007-05-31 Schering-Plough Ltd. Pharmaceutical compositions comprising buprenorphine
GB0524958D0 (en) * 2005-12-07 2006-01-18 Pharmakodex Ltd Transdermal administration of active agents
GB0524962D0 (en) * 2005-12-07 2006-01-18 Pharmakodex Ltd Topical pharmaceutical compositions
EP1962795A1 (de) * 2005-12-07 2008-09-03 PharmaKodex Ltd Topische zusammensetzungen zur anwendung bei kindern
GB0524961D0 (en) * 2005-12-07 2006-01-18 Pharmakodex Ltd Transdermal administration of active agents for systemic effect
CA2633515C (en) * 2005-12-14 2011-10-18 Jie Zhang Compositions and methods for dermally treating pain
EP1959929A4 (de) * 2005-12-14 2012-08-15 Zars Pharma Inc Zusammensetzungen und verfahren zur behandlung dermatologischer leiden
US9017717B2 (en) * 2006-01-16 2015-04-28 Peach Technologies Llc Bandage for facilitating transdermal respiration and healing
EP2682130A1 (de) 2006-01-24 2014-01-08 R-Tech Ueno, Ltd. Pharmazeutische Zusammensetzung mit einer bicyclischen Verbindung sowie Verfahren zur Stabilisierung der bicyclischen Verbindung
US8846742B2 (en) 2006-02-14 2014-09-30 The Trustees Of Columbia University In The City Of New York Neuronal pain pathway modulators
DE102006010329A1 (de) * 2006-03-06 2007-09-13 Höltge, Michael, Dipl.-Med. Hormonelles Kontrazeptivum auf der Basis eines Estrogens, eines Gestagens oder einer Kombination von Estrogenen und Gestagenen unter der Zugabe von Testosteron
US20080044462A1 (en) * 2006-04-06 2008-02-21 Collegium Pharmaceutical, Inc. Delaware Stabilized transdermal bupropion preparations
US20070248548A1 (en) * 2006-04-19 2007-10-25 Blondino Frank E Stable hydroalcoholic oral spray formulations and methods
US9468600B2 (en) 2006-05-26 2016-10-18 Dr. Holmquist Healthcare, LLC Compositions for the transdermal delivery of physiologically active agents
TW200815045A (en) * 2006-06-29 2008-04-01 Jazz Pharmaceuticals Inc Pharmaceutical compositions of ropinirole and methods of use thereof
US20080090850A1 (en) * 2006-10-13 2008-04-17 Anderson Mark E Herpetic neuralgia topical treatment
DE102006050558B4 (de) 2006-10-26 2009-03-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System enthaltend Norelgestromin zur Kontrazeption und Hormonsubstitution
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US7910597B2 (en) * 2006-11-28 2011-03-22 Shire Llc Substituted quinazolines
US8304420B2 (en) 2006-11-28 2012-11-06 Shire Llc Substituted quinazolines for reducing platelet count
JP2010513525A (ja) * 2006-12-22 2010-04-30 ノヴァデル ファーマ インコーポレイテッド 安定な抗嘔吐経口噴霧製剤および方法
AU2008205312B2 (en) * 2007-01-08 2013-11-21 Annji Pharmaceutical Co., Ltd. Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and uses thereof
AU2007343579B2 (en) * 2007-01-11 2011-11-17 Acrux Dds Pty Ltd Spreading implement
JP5319121B2 (ja) 2007-01-30 2013-10-16 株式会社東芝 診療支援システム及び診療支援装置
WO2008112661A2 (en) 2007-03-09 2008-09-18 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
US8940326B2 (en) 2007-03-19 2015-01-27 Vita Sciences Llc Transdermal patch and method for delivery of vitamin B12
WO2008128280A1 (en) * 2007-04-20 2008-10-30 Acrux Dds Pty Ltd Method and system for transdermal administration of volatile active
BRPI0811430A2 (pt) * 2007-05-10 2015-06-23 Novadel Pharma Inc Composições anti-insônia e processos
CN101730518A (zh) * 2007-05-21 2010-06-09 阿奎耶科技公司 高带电的微胶囊
HU227970B1 (en) * 2007-07-10 2012-07-30 Egis Gyogyszergyar Nyrt Pharmaceutical compositions containing silicones of high volatility
DE102007032468A1 (de) 2007-07-10 2009-01-15 Brätter, Christian, Dr. Transdermale Therapeutische Systeme, welche den Wirkstoff Anastrozol enthalten
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
AR068409A1 (es) * 2007-09-14 2009-11-18 Drugtech Corp Composiciones farmaceuticas, transdermicas sin alcohol
AR068408A1 (es) * 2007-09-14 2009-11-18 Drugtech Corp Pulverizacion de hormonas transdermicas
JP5737942B2 (ja) 2007-11-02 2015-06-17 アクルックス・ディ・ディ・エス・プロプライエタリー・リミテッドＡｃｒｕｘ Ｄｄｓ Ｐｔｙ Ｌｔｄ 経皮送達システム
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
WO2010041141A2 (en) 2008-10-07 2010-04-15 Foamix Ltd. Oil-based foamable carriers and formulations
CA2712120A1 (en) 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US20110052738A1 (en) * 2008-01-17 2011-03-03 Gary Dean Bennett Topical pain formulation
US8123082B2 (en) * 2008-01-22 2012-02-28 McNeil-AB Hand-held dispensing device
EP2247277A2 (de) * 2008-01-25 2010-11-10 B & T S.r.l. Verwendung von transverestertem olivenöl in der kosmetik
JP4879928B2 (ja) * 2008-03-25 2012-02-22 帝國製薬株式会社 ケトプロフェンリジン塩を含有する水性貼付剤
US20090259176A1 (en) * 2008-04-09 2009-10-15 Los Gatos Research, Inc. Transdermal patch system
US20110097393A1 (en) * 2008-06-25 2011-04-28 US WorldMeade, LLC Skin Patches and Sustained-Release Formulations Comprising Lofexidine for Transdermal and Oral Delivery
US20100048598A1 (en) * 2008-08-21 2010-02-25 Sateesh Kandavilli Topical compositions comprising 5-alpha reductase inhibitors
AU2009293019A1 (en) 2008-09-19 2010-03-25 Tandem Diabetes Care Inc. Solute concentration measurement device and related methods
US8748177B2 (en) * 2008-09-30 2014-06-10 The Hospital For Sick Children Compositions for proliferation of cells and related methods
KR101258336B1 (ko) 2008-10-02 2013-04-25 밀란 인크. 다층 접착제 라미네이트를 제조하는 방법
CN102307895A (zh) * 2008-12-04 2012-01-04 里兰斯坦福初级大学理事会 用于治疗或预防麻醉药停药症状的方法和组合物
CA2753214C (en) 2009-02-27 2017-07-25 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
US9250106B2 (en) 2009-02-27 2016-02-02 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
WO2010125470A2 (en) 2009-04-28 2010-11-04 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US20100298397A1 (en) * 2009-05-19 2010-11-25 Singh Nikhilesh N Method of treatment of obsessive compulsive disorder with ondansetron
US9517023B2 (en) 2009-06-01 2016-12-13 Profusa, Inc. Method and system for directing a localized biological response to an implant
WO2011013008A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
AU2010278894B2 (en) 2009-07-30 2014-01-30 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
WO2011064631A1 (en) 2009-10-02 2011-06-03 Foamix Ltd. Surfactant-free, water-free, foamable compositions and breakable foams and their uses
EP2485730A1 (de) 2009-10-09 2012-08-15 Nuvo Research Inc. Topische formulierung mit etoricoxib und einem zwitterionischen tensid
US8894630B2 (en) * 2009-11-13 2014-11-25 The Invention Science Fund I, Llc Device, system, and method for targeted delivery of anti-inflammatory medicaments to a mammalian subject
US8439896B2 (en) * 2009-11-13 2013-05-14 The Invention Science Fund I, Llc Device, system, and method for targeted delivery of anti-inflammatory medicaments to a mammalian subject
US8784368B2 (en) * 2009-11-13 2014-07-22 The Invention Science Fund I, Llc Device, system, and method for targeted delivery of anti-inflammatory medicaments to a mammalian subject
KR101955175B1 (ko) 2010-04-13 2019-03-06 나지브 바불 1-메틸-2'-6'-피페콜옥실리디드의 피부 약제학적 조성물 및 사용 방법
SG186299A1 (en) * 2010-05-04 2013-01-30 Nexmed Holdings Inc Compositions of small molecule therapeutics
US10010272B2 (en) 2010-05-27 2018-07-03 Profusa, Inc. Tissue-integrating electronic apparatus
US20120022033A1 (en) * 2010-07-23 2012-01-26 Biosante Pharmaceuticals, Inc. Methods for decreasing cardiovascular risk in postmenopausal women
US8927007B2 (en) 2010-09-17 2015-01-06 Paul Talalay Formulations for treatment with glucosinolates
CN110604585B (zh) 2010-10-06 2023-04-18 普罗弗萨股份有限公司 组织整合性传感器
EP2606895A4 (de) * 2010-10-12 2014-04-02 Univ Wuhan Pflaster zur transdermalen absorption eines antivirus-wirkstoffs und verfahren zu seiner herstellung
SE535588C2 (sv) * 2010-10-29 2012-10-02 Redsense Medical Ab Detektion av blodläckage genom påvisning av förekomsten av flyktiga ämnen
JP6912852B2 (ja) 2010-11-18 2021-08-04 ホワイト マウンテン ファーマ，インコーポレイテッド 対象における慢性または解決不能な疼痛を処置するための、および／または痛覚閾値を高めるための方法、およびこれに用いる医薬組成物
CA2827488C (en) 2011-02-15 2020-07-07 Amy Louise Marr Methods for controlling pain in equines using a transdermal solution of fentanyl
CA2827435C (en) 2011-02-15 2018-11-27 Eli Lilly And Company Methods for controlling pain in canines using a transdermal solution of fentanyl
US9119793B1 (en) 2011-06-28 2015-09-01 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for doxycycline
US8394359B1 (en) * 2011-08-26 2013-03-12 Michael P. O'Neil Tattoo removal system and method
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
WO2013078422A2 (en) 2011-11-23 2013-05-30 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CN103181956B (zh) * 2011-12-30 2015-04-29 天津市山佳医药科技有限公司 一种治疗退行性骨关节痛的透皮吸收贴剂
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US11154535B2 (en) 2012-07-31 2021-10-26 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
US10045965B2 (en) 2012-07-31 2018-08-14 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
US10045935B2 (en) 2012-07-31 2018-08-14 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
RU2657749C2 (ru) 2012-09-21 2018-06-15 Интенсити Терапьютикс, Инк Способы лечения рака
US9694050B2 (en) 2012-10-21 2017-07-04 University Of Rochester THY1 (CD90) as a novel therapy to control adipose tissue accumulation
US11707421B2 (en) 2012-11-06 2023-07-25 Colabs Int'l Corp. Compositions containing a flexible derived capsule with an active agent
US10322301B2 (en) 2012-11-06 2019-06-18 CoLabs International Corporation Compositions containing a cellulose derived capsule with a sunscreen active agent
US11491088B2 (en) 2012-11-06 2022-11-08 CoLabs International Corporation Compositions containing a capsule with a moisturizing agent
US11690793B2 (en) 2012-11-06 2023-07-04 Colabs Int'l Corp. Composition containing a cellulose derived capsule with a sunscreen
EP2916814B1 (de) 2012-11-06 2020-02-12 Colabs International Corporation Zusammensetzung mit einer aus cellulose abgeleiteten kapsel mit einem sonnenschutzmittel
US11724134B2 (en) 2012-11-06 2023-08-15 CoLabs International Corporation Compositions containing a cellulose derived capsule with a sunscreen active agent
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2014122627A1 (en) 2013-02-11 2014-08-14 Glycanova As Basidiomycete-derived cream for treatment of skin diseases
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
US10045722B2 (en) 2013-03-14 2018-08-14 Profusa, Inc. Method and device for correcting optical signals
US10842802B2 (en) 2013-03-15 2020-11-24 Medicis Pharmaceutical Corporation Controlled release pharmaceutical dosage forms
CN111544011B (zh) 2013-06-06 2023-06-06 普罗菲尤萨股份有限公司 用于探测来自植入传感器的光信号的设备和方法
USD750788S1 (en) 2013-11-26 2016-03-01 Acrux Dds Pty Ltd Topical spreading applicator
USD749225S1 (en) 2013-11-26 2016-02-09 Acrux Dds Pty Ltd Topical spreading applicator
USD752287S1 (en) 2013-12-09 2016-03-22 Amneal Pharmaceuticals Llc Applicator for applying a liquid to a surface
US9227044B2 (en) 2013-12-09 2016-01-05 Amneal Pharmaceuticals Llc Applicator for applying a fluid to a surface
WO2015100118A1 (en) * 2013-12-24 2015-07-02 The Procter & Gamble Company Cosmetic compositions and methods providing enhanced penetration of skin care actives
US9561233B2 (en) 2014-03-13 2017-02-07 Demerx, Inc. Use of ibogaine for the treatment of pain
KR102364378B1 (ko) 2014-05-21 2022-02-16 에스케이케미칼 주식회사 안정성을 향상시킨 로티고틴 함유 경피흡수제제
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11696883B2 (en) 2014-05-23 2023-07-11 Triple Hair Inc. Compositions for reducing hair loss and/or increasing hair regrowth
CN109248167A (zh) 2014-05-23 2019-01-22 特里普海尔公司 用于减少脱发和/或增加毛发再生的组合物
US20160022643A1 (en) * 2014-07-22 2016-01-28 Professional Compounding Centers Of America Oral Transmucosal Compositions including Aromatase Inhibitors for Low Testosterone Levels in Men
US9592239B2 (en) 2014-09-12 2017-03-14 Demerx, Inc. Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake
US10213586B2 (en) 2015-01-28 2019-02-26 Chrono Therapeutics Inc. Drug delivery methods and systems
US9918998B2 (en) 2015-03-23 2018-03-20 BioPharmX, Inc. Pharmaceutical tetracycline composition for dermatological use
US20160307158A1 (en) * 2015-04-16 2016-10-20 Linkedin Corporation Aggregating and transforming user actions into social signal features for a job recommendation engine
PT3347009T (pt) 2015-07-08 2022-01-12 Triple Hair Inc Composição compreendendo resveratrol e melatonina para reduzir a perda de cabelo e/ou aumentar o crescimento do cabelo
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10549129B2 (en) 2016-06-24 2020-02-04 The Procter & Gamble Company Cosmetic compositions and methods providing enhanced penetration of skin care actives
MX2020012139A (es) 2016-09-08 2021-01-29 Vyne Pharmaceuticals Inc Composiciones y metodos para tratar rosacea y acne.
KR102499141B1 (ko) 2016-10-31 2023-02-13 신신제약 주식회사 수면장애 치료용 경피흡수제제
WO2018118197A1 (en) * 2016-12-21 2018-06-28 Richard Postrel Healthier aging in domesticated animals
WO2018119400A1 (en) 2016-12-22 2018-06-28 Profusa, Inc. System and single-channel luminescent sensor for and method of determining analyte value
CA3049529A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
US10396053B2 (en) * 2017-11-17 2019-08-27 General Electric Company Semiconductor logic device and system and method of embedded packaging of same
WO2019140087A1 (en) * 2018-01-10 2019-07-18 Celista Pharmaceuticals Llc Testosterone transdermal spray with film
CA3101966A1 (en) 2018-05-29 2019-12-05 Morningside Venture Investments Limited Drug delivery methods and systems
AU2019291885A1 (en) 2018-06-27 2021-02-04 CoLabs International Corporation Compositions comprising silicon dioxide-based particles including one or more agents
AU2019381810A1 (en) * 2018-11-16 2021-06-03 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
CN114007617A (zh) * 2019-05-31 2022-02-01 葡瑞慕生物技术有限公司 用于经黏膜给药药物活性成分的单位剂型
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
KR102503159B1 (ko) 2020-04-29 2023-02-23 신신제약 주식회사 멜라토닌을 함유하는 경피흡수제제

Family Cites Families (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE555319A (de) * 1956-03-21 1900-01-01
GB867904A (en) * 1959-07-27 1961-05-10 Farmilai Farmaceutici Soc Spraying apparatus
US3211250A (en) * 1962-12-21 1965-10-12 Garfield A Wood Seat-actuated brake and switch arrangement for motor vehicles
US3306252A (en) * 1963-12-03 1967-02-28 Johnson & Johnson Shielded aerosol medicament dispenser
US3993073A (en) 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3797494A (en) 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4069307A (en) 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
AT330643B (de) * 1971-04-23 1976-07-12 Laake Oy Aerosoleinrichtung
US3731683A (en) 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
BE795384A (fr) 1972-02-14 1973-08-13 Ici Ltd Pansements
US3921636A (en) 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
US3993072A (en) 1974-08-28 1976-11-23 Alza Corporation Microporous drug delivery device
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4060084A (en) 1976-09-07 1977-11-29 Alza Corporation Method and therapeutic system for providing chemotherapy transdermally
US4975272A (en) * 1976-11-10 1990-12-04 Voyt Walter F Method of and composition for the prevention of solar radiation exposure-induced formation of carcinogenic skin lipid degradation products
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
DK534178A (da) 1977-12-16 1979-06-17 Interx Research Corp Anticholinerge midler med sektrtionshaemmende virkning
JPS5562012A (en) 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
US4230105A (en) 1978-11-13 1980-10-28 Merck & Co., Inc. Transdermal delivery of drugs
US4954487A (en) 1979-01-08 1990-09-04 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
US4291015A (en) 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US4299826A (en) 1979-10-12 1981-11-10 The Procter & Gamble Company Anti-acne composition
US4310511A (en) * 1980-10-02 1982-01-12 Massachusetts General Hospital Sunscreen compositions containing Δ5,7 steroidal dienes
US4938951A (en) * 1980-12-30 1990-07-03 Union Carbide Chemicals And Plastics Company Inc. Potentiation of topical compositions wherein a uniform microdispersion of active agent is formed
US4440777A (en) 1981-07-07 1984-04-03 Merck & Co., Inc. Use of eucalyptol for enhancing skin permeation of bio-affecting agents
US4557934A (en) 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
JPS60155111A (ja) * 1983-10-20 1985-08-15 Hisamitsu Pharmaceut Co Inc 安定なケトプロフェン含有外用経皮製剤
US4563346A (en) 1984-03-14 1986-01-07 Charles Of The Ritz Group Ltd. Topical delivery system and skin treatment compositions employing such system
US4824676A (en) * 1984-10-11 1989-04-25 Schering Corporation Physiological means of enhancing transdermal delivery of drugs
US5008111A (en) * 1984-10-11 1991-04-16 Schering Corporation Physiological means of enhancing transdermal delivery of drugs
JPS61268631A (ja) 1985-05-22 1986-11-28 Showa Denko Kk 経皮吸収性を高めた皮膚外用剤
EP0189861A3 (de) * 1985-01-26 1988-02-17 Showa Denko Kabushiki Kaisha Transdermaler Absorptionsbeschleuniger für ionische wasserlösliche Arzneistoffe
US4663157A (en) * 1985-02-28 1987-05-05 The Proctor & Gamble Company Sunscreen compositions
DE3522550A1 (de) 1985-06-24 1987-01-02 Klinge Co Chem Pharm Fab Aufspruehbare pharmazeutische zubereitung fuer die topische anwendung
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
ATE84667T1 (de) 1986-01-31 1993-02-15 Whitby Research Inc Hautpenetration verbessernde zusammensetzungen.
US5256647A (en) 1986-01-31 1993-10-26 Whitby Research, Inc. Compositions comprising 1-substituted azacycloalkanes
US4699779A (en) * 1986-02-18 1987-10-13 Victor Palinczar Waterproof sunscreen compositions
LU86368A1 (fr) * 1986-03-24 1987-11-11 Oreal Procede pour preparer et distribuer un produit comprenant au moins deux composants,et dispositif pour sa mise en oeuvre
US4820724A (en) 1986-03-31 1989-04-11 University Of Southern California Dual phase solvent carrier system
US5196410A (en) 1986-10-31 1993-03-23 Pfizer Inc. Transdermal flux enhancing compositions
US4861764A (en) 1986-11-17 1989-08-29 Macro Chem. Corp. Percutaneous absorption enhancers, compositions containing same and method of use
US5179079A (en) * 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
US4940586A (en) * 1987-02-26 1990-07-10 Alza Corporation Skin permeation enhancer compositions using sucrose esters
EP0281395A3 (de) * 1987-03-06 1990-10-10 Richardson-Vicks, Inc. Feuchtigkeitsspendende Emulsion für die Haut
BE1000381A4 (fr) 1987-03-13 1988-11-16 Pharlyse Sa Preparation pharmaceutique a base d'indometacine.
US5030442A (en) 1987-03-30 1991-07-09 Liposome Technology, Inc. Non-crystalline minoxidil composition
US5082656A (en) * 1987-04-30 1992-01-21 Abbott Laboratories Topical antibacterial compositions containing penetration enchancers
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4954332A (en) * 1987-10-22 1990-09-04 The Procter & Gamble Company Photoprotection compositions comprising tocopherol sorbate and an anti-inflammatory agent
US4946671A (en) * 1987-10-22 1990-08-07 The Procter & Gamble Company Photoprotection compositions comprising sorbohydroxamic acid and an anti-inflammatory agent
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
IE62871B1 (en) * 1988-03-08 1995-03-08 Warner Lambert Co Compositions with enhanced penetration
US5017365A (en) * 1988-05-09 1991-05-21 Solarcare Technologies Corporation Sunscreen composition and applicator system
US5082866A (en) 1988-06-01 1992-01-21 Odontex, Inc. Biodegradable absorption enhancers
US5164406A (en) 1988-06-02 1992-11-17 Bristol-Myers Squibb Co. Method for enhancing transdermal penetration and compositions useful therein
US5487989A (en) * 1988-08-31 1996-01-30 Bioenergy International, L.C. Ethanol production by recombinant hosts
US5332577A (en) * 1988-12-27 1994-07-26 Dermamed Transdermal administration to humans and animals
US5192534A (en) * 1988-12-30 1993-03-09 L'oreal Composition for inducing and stimulating hair growth and/or retarding its loss, based on pyrimidine derivatives and sunscreens
US4917882A (en) * 1989-03-16 1990-04-17 Amway Corporation Gel-type sunscreen composition
US4959205A (en) 1989-03-23 1990-09-25 Collagen Corporation Composition and method for treatment of dermal inflammation
US5093360A (en) * 1989-04-07 1992-03-03 Yu Ruey J Retinal, derivatives and their therapeutic use
IT8920486A0 (it) * 1989-05-12 1989-05-12 Isf Spa Composizioni farmaceutiche.
EP0404334B1 (de) * 1989-05-19 1994-02-02 Beecham Group p.l.c. Aerosolzusammensetzungen zur topischen Anwendung
US5100918A (en) * 1989-05-25 1992-03-31 Sterling Drug, Inc. Prevention or treatment of sunburn using the S(+) isomer of ibuprofen
FR2648133B1 (fr) * 1989-06-08 1992-02-21 Sanofi Sa Lauramides n-substitues, leur preparation et compositions les contenant
US5122519A (en) * 1989-06-27 1992-06-16 American Cyanamid Company Stable, cosmetically acceptable topical gel formulation and method of treatment for acne
US5219877A (en) * 1989-09-25 1993-06-15 Bristol-Myers Squibb Company Lauryl alcohol as skin penetration enhancer for topical imidazole agents
US5023085A (en) 1989-11-29 1991-06-11 Pfizer Inc. Transdermal flux enhancers in combination with iontophoresis in topical administration of pharmaceuticals
WO1991007944A1 (en) 1989-12-04 1991-06-13 Richardson-Vicks, Inc. Photoprotective compositions
US5115805A (en) 1990-02-23 1992-05-26 Cygnus Therapeutic Systems Ultrasound-enhanced delivery of materials into and through the skin
SG45171A1 (en) * 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
ATE156353T1 (de) * 1990-09-05 1997-08-15 Ciba Geigy Ag Arachidonsäurestoffwechselhemmende diphenylverbindungen und ihre verwendung in pharmazeutischen zusammensetzungen
US5202125A (en) * 1990-12-10 1993-04-13 Theratech, Inc. Method and systems for administering nitroglycerin transdermally at enhanced transdermal fluxes
US5674912A (en) 1991-03-01 1997-10-07 Warner-Lambert Company Sunscreen-wound healing compositions and methods for preparing and using same
TW213418B (de) 1991-05-02 1993-09-21 Kuko Seiyaku Kk
WO1992019592A1 (en) * 1991-05-09 1992-11-12 Shiseido Co., Ltd Cinnamic acid/glycerol adduct, ultraviolet absorber, and dermatologic preparation
TW206918B (de) 1991-05-11 1993-06-01 Kuko Seiyaku Kk
US5212199A (en) * 1991-05-17 1993-05-18 Theratech, Inc. Sorbitan esters as skin permeation enhancers
JPH06509099A (ja) * 1991-07-03 1994-10-13 サノ・コーポレーシヨン ジクロフエナツクの経皮デリバリーに対する組成物及び方法
US5487898A (en) 1991-08-26 1996-01-30 Abbott Laboratories Compositions and method for the sublingual or buccal administration therapeutic agents
EG20380A (en) 1991-10-16 1999-02-28 Richardson Vicks Inc Enhanced skin penetration system for improved topical delivery of drugs
JPH07501540A (ja) 1991-11-25 1995-02-16 リチャードソン、ビックス、インコーポレーテッド 皮膚シワ及び／又は皮膚萎縮を調節するための組成物
EP0614354B1 (de) 1991-11-25 2001-01-17 Richardson-Vicks, Inc. Verwendungvon salicylsäure zur kontrolle der hautatrophie
JP3722293B2 (ja) * 1991-12-18 2005-11-30 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 新規な薬学的固体分散物
JP3202777B2 (ja) * 1992-01-24 2001-08-27 リンテック株式会社 経皮吸収促進剤及びテープ製剤
US5446025A (en) * 1992-06-12 1995-08-29 Abbott Laboratories Formulations and method of the percutaneous administration of leuprolide
CA2101496A1 (en) 1992-07-31 1994-02-01 Masao Kobayashi Base for transdermal administration
JP3453843B2 (ja) * 1993-06-08 2003-10-06 ソニー株式会社 ディスク装置
FR2708000B1 (fr) * 1993-07-22 1995-08-25 Pechiney Aluminium Aluminium électroraffiné à basse teneur en uranium, thorium et terres rares.
US5460820B1 (en) 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women
DE4334553C2 (de) 1993-10-11 1998-05-20 Synopharm Gmbh Pharmazeutische Flüssiges pharmazeutisches System zur perkutanen Applikation
FR2714602B1 (fr) * 1993-12-30 1996-02-09 Oreal Composition antiacnéique pour le traitement simultané des couches superficielles et profondes de la peau, son utilisation.
DE4400770C1 (de) * 1994-01-13 1995-02-02 Lohmann Therapie Syst Lts Wirkstoffhaltiges Pflaster zur Abgabe von Estradiol mit mindestens einem Penetrationsverstärker, Verfahren zu seiner Herstellung und seine Verwendung
US5508023A (en) * 1994-04-11 1996-04-16 The Center For Innovative Technology Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant
US5505935A (en) * 1994-05-09 1996-04-09 Elizabeth Arden Company, Division Of Conopco, Inc. Sunscreen compositions
US5508168A (en) * 1994-05-16 1996-04-16 Hoffmann-La Roche Inc. Methods and reagents for the detection of herpes simplex virus, treponema pallidum, and haemophilus ducreyi
US5449519C1 (en) * 1994-08-09 2001-05-01 Revlon Consumer Prod Corp Cosmetic compositions having keratolytic and anti-acne activity
GB9504265D0 (en) * 1995-03-03 1995-04-19 Medeva Plc Corticosteroid-containing pharmaceutical composition
FR2732223B1 (fr) 1995-03-30 1997-06-13 Sanofi Sa Composition pharmaceutique pour administration transdermique
DE19521951A1 (de) * 1995-06-08 1996-12-12 Lancaster Group Ag Mehrphasiges Lichtschutzmittel, Verfahren zur Herstellung und zum Auftragen auf die Haut
US6916487B2 (en) * 1996-02-19 2005-07-12 Acrux Dds Pty Ltd Transdermal delivery of antiemetics
US6929801B2 (en) * 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US6923983B2 (en) * 1996-02-19 2005-08-02 Acrux Dds Pty Ltd Transdermal delivery of hormones
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US7094422B2 (en) * 1996-02-19 2006-08-22 Acrux Dds Pty Ltd. Topical delivery of antifungal agents
US6916486B2 (en) * 1996-02-19 2005-07-12 Acrux Dds Pty Ltd Transdermal delivery of analgesics
US6998138B2 (en) * 1996-02-19 2006-02-14 Acrux Dds Pty. Ltd. Topical delivery of anti-alopecia agents
US6004969A (en) 1996-04-15 1999-12-21 National Science Council Transdermal delivery of buprenorphine preparations
AUPO379596A0 (en) 1996-11-22 1996-12-19 Soltec Research Pty Ltd Percutaneous delivery system
US5804168A (en) * 1997-01-29 1998-09-08 Murad; Howard Pharmaceutical compositions and methods for protecting and treating sun damaged skin
IT1294748B1 (it) * 1997-09-17 1999-04-12 Permatec Tech Ag Formulazione per un dispositivo transdermico
US5968919A (en) 1997-10-16 1999-10-19 Macrochem Corporation Hormone replacement therapy drug formulations for topical application to the skin
US6101716A (en) * 1998-02-12 2000-08-15 Schulz; Steven L. Evaporative cooler solar retrofit kit
ES2193726T3 (es) * 1998-08-04 2003-11-01 Jago Res Ag Formulaciones de aerosol medicinales.
IL144729A0 (en) 1999-02-05 2002-06-30 Cipla Ltd Topical sprays
US6399093B1 (en) * 1999-05-19 2002-06-04 Advanced Medical Instruments Method and composition to treat musculoskeletal disorders
CN1240384C (zh) * 1999-11-04 2006-02-08 美国爱科赛尔制药有限公司 石杉碱经皮给药制剂
WO2001041755A2 (en) 1999-12-02 2001-06-14 The Regents Of The University Of Michigan Topical compositions comprising thalidomide for the treatment of inflammatory diseases
US6432415B1 (en) * 1999-12-17 2002-08-13 Axrix Laboratories, Inc. Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US6387383B1 (en) * 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
IN191090B (de) 2000-08-29 2003-09-20 Ranbanx Lab Ltd
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
BR0113649A (pt) 2000-08-30 2004-07-20 Unimed Pharmaceuticals Inc Processo para aumentar a testosterona e as relacionadas concentrações de esteróide em mulheres
EP1315502B1 (de) 2000-08-30 2010-03-17 Unimed Pharmaceuticals, LLC Verfahren zur behandlung von erektionsstörungen und steigerung der libido bei männern
US6682757B1 (en) * 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
US6743448B2 (en) * 2000-12-11 2004-06-01 Abraham H. Kryger Topical testosterone formulations and associated methods
EP1511494B1 (de) 2002-03-15 2020-08-19 Unimed Pharmaceuticals, LLC Pharmazeutische androgen-zusammensetzung und verfahren zur behandlung von depressionen
US20030199584A1 (en) * 2002-04-11 2003-10-23 Ahluwalia Gurpreet S. Reduction of hair growth
US20050181032A1 (en) * 2002-06-25 2005-08-18 Acrux Dds Pty Ltd. Metastable pharmaceutical compositions
US20050186141A1 (en) 2002-06-25 2005-08-25 Acrux Dds Pty Ltd. Transdermal aerosol compositions
NZ537360A (en) * 2002-06-25 2006-09-29 Acrux Dds Pty Ltd Transdermal delivery rate control using amorphous pharmaceutical compositions
FR2851470B1 (fr) * 2003-02-20 2007-11-16 Besins Int Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse
CA2433101A1 (en) * 2003-06-23 2004-12-23 Igor Gonda Method of treatment of a female suffering from androgen insufficiency
US6923226B2 (en) * 2003-07-01 2005-08-02 Patrick Wesley Bartlett Device for preventing entry of an unleaded gas fill nozzle in a diesel fuel filler neck
US20050025833A1 (en) * 2003-07-16 2005-02-03 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050042268A1 (en) * 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050020552A1 (en) * 2003-07-16 2005-01-27 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
MXPA06003316A (es) 2003-10-10 2006-06-08 Antares Pharma Ipl Ag Formulacion farmaceutica transdermica para minimizar los residuos en la piel.
JP2007511544A (ja) * 2003-11-19 2007-05-10 アクルックス・ディ・ディ・エス・プロプライエタリー・リミテッド アミロイド症の予防若しくは治療のための組成物および方法
US20050123575A1 (en) 2003-12-03 2005-06-09 Eilon Asculai Spreadable compositions for topical use, an improved process of making same and methods of using same
CN1946431B (zh) * 2004-03-03 2011-12-07 雷文斯治疗公司 用于肉毒毒素的局部施用和透皮递送的组合物和方法
AU2006249761A1 (en) * 2005-05-25 2006-11-30 Transcept Pharmaceuticals, Inc. Solid compositions and methods for treating middle-of-the night insomnia
ES2607454T3 (es) * 2005-06-03 2017-03-31 Acrux Dds Pty Ltd Método y composición para el suministro transdérmico de testosterona

Also Published As

Publication number Publication date
DE122012000019I1 (de) 2012-06-14
EP1674068B1 (de) 2008-10-08
LU91971I2 (fr) 2012-06-04
US7438203B2 (en) 2008-10-21
PT1674068E (pt) 2008-12-11
DE69739931D1 (de) 2010-08-19
AU706967B2 (en) 1999-07-01
NZ330942A (en) 1999-11-29
JP4213211B2 (ja) 2009-01-21
KR19990087057A (ko) 1999-12-15
US20040009214A1 (en) 2004-01-15
ES2314538T3 (es) 2009-03-16
LU91972I2 (fr) 2012-06-04
US20080152597A1 (en) 2008-06-26
HK1101553A1 (en) 2007-10-18
JP2000504697A (ja) 2000-04-18
LU91973I2 (fr) 2012-06-04
DK1769785T3 (da) 2010-10-25
US20070077288A1 (en) 2007-04-05
EP1674068A1 (de) 2006-06-28
EP1769785A1 (de) 2007-04-04
CA2244089C (en) 2009-06-02
CA2244089A1 (en) 1997-08-21
ES2348313T3 (es) 2010-12-02
DE69739037D1 (de) 2008-11-20
DK0901368T3 (da) 2006-09-04
DE69735804T2 (de) 2006-12-14
ATE324865T1 (de) 2006-06-15
US6299900B1 (en) 2001-10-09
US6818226B2 (en) 2004-11-16
EP1769785B1 (de) 2010-07-07
PT901368E (pt) 2006-09-29
ATE410136T1 (de) 2008-10-15
WO1997029735A1 (en) 1997-08-21
ES2262173T3 (es) 2006-11-16
EP0901368A4 (de) 2000-01-26
HK1018884A1 (en) 2000-01-07
HK1087355A1 (en) 2006-10-13
US20020028235A1 (en) 2002-03-07
ATE472997T1 (de) 2010-07-15
PT1769785E (pt) 2010-08-26
KR100528602B1 (ko) 2007-03-15
US20080131494A1 (en) 2008-06-05
US20040146469A1 (en) 2004-07-29
EP0901368A1 (de) 1999-03-17
US8071075B2 (en) 2011-12-06
DK1674068T3 (da) 2009-02-09
US7387789B2 (en) 2008-06-17
AU1713497A (en) 1997-09-02
EP0901368B1 (de) 2006-05-03
DE122012000021I1 (de) 2012-07-12
DE122012000020I1 (de) 2012-06-14
US20070071803A1 (en) 2007-03-29
AUPN814496A0 (en) 1996-03-14
JP2007326867A (ja) 2007-12-20
US6964777B2 (en) 2005-11-15

Similar Documents

Publication Publication Date Title
DE69735804D1 (de) Hautpenetrationsförderer sowie diese verwendende arzneiverabreichungssysteme
CA1329547C (en) Skin permeation enhancer compositions using glycerol monooleate
DE3277453D1 (en) Use of eucalyptol for enhancing skin permeation of bioaffecting agents
KR950701516A (ko) 옥시부티닌의 경피 투여(Transdermal Administration of Oxybutynin)
KR910014117A (ko) 하이드로알콜성 겔을 사용한 이부프로펜의 경피전달 방법
MX9708722A (es) Metodos y composiciones para mejorar la permeacion de la piel a los farmacos utilizando mejoradores de la permeacion, cuando los farmacos y/o los mejoradores de la permeacion son inestables en combinacion durante el almacenamiento a largo plazo.
ES2191834T3 (es) Agentes que facilitan la permeacion y destinados para composiciones, dispositivos y procedimientos de aporte transdermico de medicamentos.
KR890003413A (ko) 이중 침투증대제를 가진 경피식 약물투여장치
ATE184473T1 (de) Verwendung von glyzerin zur dämpfung der transdermalen arzneimittelverabreichung
ES2117042T3 (es) Sistemas para administrar farmacos transdermicamente utilizando esteres de sorbitan como intensificadores de la penetrabilidad en la piel.
AU1313299A (en) Penetration enhancing and irritation reducing systems
ES2171469T3 (es) Composicion administrada por via nasal y preparacion que la contiene.
DE69735656D1 (de) Neue Formulierungen zur transdermale Verabreichung von Fluoxetin
DE69229318T2 (de) Hydrierte Rizinusöl-enthaltende injizierbare Formulierungen mit verlängerter Wirkstoffabgabe
US4476115A (en) Analgesic composition and method of treating subdermal pain
KR930700110A (ko) 세포독성제 및 침투 증진제로 이루어진 조성물
ATE212222T1 (de) Zusammensetzungen zur transdermalen und dermalen verabreichung von biologisch wirksamen stoffen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition